Endocrine Research

CJC-1295 (no DAC) + Ipamorelin 10mg

EGX-CJCIPA-10

10 mg / vial

IN STOCKCOA AVAILABLE>99% (HPLC) PURITY

Research combination targeting complementary growth-hormone release pathways; direct evidence for the exact blend remains limited.

Investigated mechanism

Combination of two complementary signals: a GHRH-related analog and ipamorelin, an agonist of the GH-secretagogue/ghrelin receptor. Most human literature on CJC-1295 covers the long-acting DAC version, so evidence for this exact no-DAC blend is limited.

Research areas

Pulsatile GH release
Pituitary signaling
GH–IGF-1 axis
Experimental endocrinology

Level of evidence

Limited human data. Studies are small, specialized or regionally concentrated.

Specifications

Identity

SKU: EGX-CJCIPA-10
Form: Lyophilized powder

Composition

Purity: >99% (HPLC)

Handling & supply

Presentation: 10 mg / vial
Storage: Store at -20 C, protect from light

Documentation

Certificate of Analysis · issued per lot

COA · PDF

Private pricing

Checking access…

Sold for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use.